Back to Research Home
NEOGNeogen Corporation
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · Mid
$12.19+1.75%
As of 23 Oct 2026Mkt cap $2.6B
Stage 13
AVOID
Fundamentals
8.6/75
Technical
6.4/15
Independent
15.0/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- −10.8%
- 3M
- +30.5%
- 6M
- +27.8%
- 1Y
- +98.5%
Financials & valuation
Cached filing evidence · as of 2026-10-07
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 53.3x
- FCF yield
- 1.9%
Quality
- ROIC
- —
- Operating margin
- -2.5%
- FCF margin
- 3.7%
- Current ratio
- 3.8x
Growth
- Revenue growth
- −2.7%Latest FY YoY
- Revenue CAGR
- +13.4%
- EPS CAGR
- —
- FCF CAGR
- −7.5%
Capital
- Share-count trend
- +0.2%3Y annualised
- Net debt
- $627M7.5x OCF
Annual trend
- CAGR 2022–2026
- +13.4%
- Latest · 2026
- $1B
- YoY
- −2.7%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2027-01-07
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-07
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded